TBCB

Across TCGA pan-cancer cohorts, TBCB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBCB data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBCB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TBCB expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TBCB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.808	1.000	.001	37	view →
PDAC	DFS	Quartile	All	0.457	0.290	.009	23	view →
LUAD	OS	Median	II,III,IV	0.280	0.800	.003	8	view →
GBM	DFS	Tertile	All	0.295	0.545	.019	4	view →
LSCC	OS	Median	All	0.750	0.869	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBCB–CCRCC (OS)

Open the CCRCC breakdown →